U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H16ClNO3
Molecular Weight 305.756
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOLDOPAM

SMILES

OC1=CC=C(C=C1)C2CNCCC3=C(Cl)C(O)=C(O)C=C23

InChI

InChIKey=TVURRHSHRRELCG-UHFFFAOYSA-N
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2

HIDE SMILES / InChI

Molecular Formula C16H16ClNO3
Molecular Weight 305.756
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Fenoldopam (marketed under the brand name Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. Fenoldopam Mesylate Injection, USP is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.

CNS Activity

Curator's Comment: Fenoldopam does not cross the blood-brain barrier

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CORLOPAM

Approved Use

Adult Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusion. Pediatric Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 4 hours) reduction in blood pressure.

Launch Date

8.7497277E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
26.5 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
26.8 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
44.7 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
2.9 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 ug/kg/min single, intravenous
Highest studied dose
Dose: 1.5 ug/kg/min
Route: intravenous
Route: single
Dose: 1.5 ug/kg/min
Sources: Page: 1-61
unhealthy, 46±3
n = 9
Health Status: unhealthy
Condition: Hypertension
Age Group: 46±3
Sex: M+F
Population Size: 9
Sources: Page: 1-61
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disc. AE: Tachycardia, Hypokalemia...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Hypokalemia
Anaphylactic reaction
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Anaphylactic reaction Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Hypokalemia Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Tachycardia Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
1992 Jan
Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats.
2000 Sep-Oct
Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
2001
Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
2001
Histopathological and immunohistochemical studies on arteritis induced by fenoldopam, a vasodilator, in rats.
2001 Apr
[Fenoldopam: potential clinical applications in heart surgery].
2001 Dec
The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery.
2001 Feb
Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
2001 Jan-Feb
Reduced regional and global cerebral blood flow during fenoldopam-induced hypotension in volunteers.
2001 Jul
D(1) dopamine receptor regulation of NHE3 during development in spontaneously hypertensive rats.
2001 Jun
Preventing contrast-induced nephropathy with fenoldopam.
2001 Mar
Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study.
2001 May
[Regulation of NHE3 by D1 dopamine receptor during development of spontaneously hypertensive rats].
2001 May 10
Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.
2001 Nov 22
Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside.
2001 Oct
Fenoldopam in the prevention of contrast media-induced acute renal failure.
2001 Oct
Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats.
2002 Apr
Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
2002 Apr 15
Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature.
2002 Dec
A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
2002 Feb
The effects of fenoldopam on renal function in patients undergoing elective aortic surgery.
2002 Jan
Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
2002 Jul
Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
2002 May
The therapeutic potential of dopamine modulators on the cardiovascular and renal systems.
2002 May
Stability of fenoldopam mesylate in two infusion solutions.
2002 May 1
In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission.
2002 May 31
Contrast-associated nephropathy.
2002 Nov-Dec
Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
2002 Sep
New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists.
2002 Winter
Hypertensive emergencies. Etiology and management.
2003
The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.
2003
Pharmacologic identification of putative D1 dopamine receptors in feline kidneys.
2003 Aug
The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine.
2003 Feb
The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery.
2003 Feb
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
2003 Jan 1
Dopamine D1 receptor-dependent inhibition of NaCl transport in the rat thick ascending limb: mechanism of action.
2003 Jul 25
Receptor mechanisms of prenodal lymphatic constriction by dopamine.
2003 Jun 15
Galpha12- and Galpha13-protein subunit linkage of D5 dopamine receptors in the nephron.
2003 Mar
Radiocontrast-induced nephropathy.
2003 Mar-Apr
Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats.
2003 May
N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
2004 Aug 18
Optimization of intestinal mucosal oxygenation in shock: a role for medical therapy?
2004 Jan
Dopamine under alpha1-blockade, but not dopamine alone or fenoldopam, increases depressed gastric mucosal oxygenation.
2004 Jan
Periprocedural hypertension: current concepts in management for the vascular surgeon.
2004 Jul-Aug
Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.
2004 Jun
Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock.
2004 Sep
Patents

Sample Use Guides

Adults: Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous infusion. Dosing can be increased in increments of 0.05 to 0.1 mcg/kg/minute every 15 minutes or longer until target blood pressure is reached. Dilute prior to administration Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a maximum dose of 0.8 mcg/kg/minute
Route of Administration: Intravenous
Incubation of freshly isolated mouse kidney slices with the selective D(1)-like receptor agonists fenoldopam (10 uM) and SKF-38393 (10 uM) for 1 h induced NaPi-IIa internalization and reduced expression of NaPi-IIa in the brush border membrane (BBM).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:00:19 UTC 2023
Edited
by admin
on Wed Jul 05 23:00:19 UTC 2023
Record UNII
INU8H2KAWG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOLDOPAM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
FENOLDOPAM [MI]
Common Name English
Fenoldopam [WHO-DD]
Common Name English
CARLACOR
Brand Name English
fenoldopam [INN]
Common Name English
FENOLDOPAM [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
WHO-ATC C01CA19
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
NDF-RT N0000175580
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
NDF-RT N0000000117
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
WHO-VATC QC01CA19
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID0043896
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
PUBCHEM
3341
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
DRUG BANK
DB00800
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
RXCUI
24853
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY RxNorm
IUPHAR
939
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
WIKIPEDIA
FENOLDOPAM
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
SMS_ID
100000081281
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
INN
4673
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
NCI_THESAURUS
C61759
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
MESH
D018818
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
DAILYMED
INU8H2KAWG
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
MERCK INDEX
M5280
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY Merck Index
CHEBI
5002
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
DRUG CENTRAL
1153
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
LACTMED
Fenoldopam
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
CAS
67227-56-9
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
EVMPD
SUB07577MIG
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
FDA UNII
INU8H2KAWG
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
ChEMBL
CHEMBL588
Created by admin on Wed Jul 05 23:00:19 UTC 2023 , Edited by admin on Wed Jul 05 23:00:19 UTC 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
BINDER->LIGAND
BINDING
ENANTIOMER -> RACEMATE
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC